Pares et al evaluated the response to ursodeoxycholic acid (UDCA) therapy in a patient with primary biliary cirrhosis (PBC). This can help to identify a patient who may benefit from more aggressive management. The authors are from Institut d'investigacions Biomèdiques August Pi i Sunyer(IDIAPS) in Barcelona.